Dimensional Fund Advisors LP Has $3.19 Million Stake in NeoGenomics, Inc. (NEO)
Dimensional Fund Advisors LP increased its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 172.8% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 404,626 shares of the medical research company’s stock after buying an additional 256,282 shares during the period. Dimensional Fund Advisors LP owned approximately 0.51% of NeoGenomics worth $3,192,000 at the end of the most recent reporting period.
Other large investors also recently added to or reduced their stakes in the company. Cambridge Investment Research Advisors Inc. boosted its stake in NeoGenomics by 7.9% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 13,600 shares of the medical research company’s stock valued at $107,000 after buying an additional 1,000 shares during the period. Campbell & CO Investment Adviser LLC boosted its stake in NeoGenomics by 10.4% in the first quarter. Campbell & CO Investment Adviser LLC now owns 15,009 shares of the medical research company’s stock valued at $118,000 after buying an additional 1,419 shares during the period. Principal Financial Group Inc. boosted its stake in NeoGenomics by 2.5% in the first quarter. Principal Financial Group Inc. now owns 22,164 shares of the medical research company’s stock valued at $175,000 after buying an additional 545 shares during the period. Trexquant Investment LP bought a new stake in NeoGenomics during the first quarter valued at approximately $178,000. Finally, Suntrust Banks Inc. boosted its stake in NeoGenomics by 0.6% in the first quarter. Suntrust Banks Inc. now owns 31,617 shares of the medical research company’s stock valued at $249,000 after buying an additional 184 shares during the period. Institutional investors and hedge funds own 80.81% of the company’s stock.
NeoGenomics, Inc. (NASDAQ:NEO) traded up 2.99% on Thursday, reaching $10.00. The company’s stock had a trading volume of 306,959 shares. NeoGenomics, Inc. has a 52-week low of $6.90 and a 52-week high of $10.20. The firm has a 50-day moving average price of $9.26 and a 200 day moving average price of $8.30. The firm’s market capitalization is $793.88 million.
NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings data on Tuesday, July 25th. The medical research company reported $0.04 EPS for the quarter, beating the Zacks’ consensus estimate of $0.01 by $0.03. The firm had revenue of $66.09 million for the quarter, compared to analyst estimates of $62.95 million. NeoGenomics had a positive return on equity of 6.09% and a negative net margin of 2.81%. The business’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same period last year, the company earned $0.04 EPS. Equities analysts anticipate that NeoGenomics, Inc. will post $0.18 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Dimensional Fund Advisors LP Has $3.19 Million Stake in NeoGenomics, Inc. (NEO)” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://www.watchlistnews.com/dimensional-fund-advisors-lp-has-3-19-million-stake-in-neogenomics-inc-neo/1534437.html.
Several equities research analysts have recently commented on the company. Cantor Fitzgerald set a $11.00 price target on NeoGenomics and gave the stock a “buy” rating in a research note on Saturday, May 27th. ValuEngine upgraded NeoGenomics from a “sell” rating to a “hold” rating in a research note on Monday, August 7th. BidaskClub cut NeoGenomics from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th. Zacks Investment Research cut NeoGenomics from a “hold” rating to a “sell” rating in a research note on Tuesday, June 27th. Finally, BTIG Research restated a “buy” rating and set a $11.00 price target on shares of NeoGenomics in a research note on Sunday, May 28th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $10.17.
In other news, Director Alison L. Hannah acquired 20,000 shares of the firm’s stock in a transaction on Thursday, July 27th. The shares were purchased at an average cost of $9.19 per share, for a total transaction of $183,800.00. Following the transaction, the director now owns 38,782 shares of the company’s stock, valued at $356,406.58. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Jennifer Balliet sold 10,723 shares of the stock in a transaction on Thursday, June 22nd. The shares were sold at an average price of $8.49, for a total value of $91,038.27. The disclosure for this sale can be found here. 12.20% of the stock is currently owned by company insiders.
NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.
Receive News & Ratings for NeoGenomics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.